Intravitreal injections are injections of anti-VEGF (Vascular Endothelial Growth Factor which is responsible for growth of new vessels) into the vitreous cavity of the eyeball to prevent the growth of these abnormal new blood vessels.
Avastin is used in the treatment for wet (neovascular) AMD (macular degeneration).
Avastin is injected into the eye to control the growth of abnormal blood vessels in AMD. It binds and inhibits VEGF activity. Depending on individual’s condition, repeated injections at regular intervals (4 to 6 weeks) are required to achieve desired results.
Lucentis is also used in the treatment for wet (neovascular) AMD (macular degeneration).
Lucentis is classified in the group of anti-angiogenic drug which acts against the development of new blood vessels. It binds and inhibits VEGF activity. It is a form of Avastin however in smaller molecules to increase penetration of the retina. Just like in the case of Avastin, repeated injections at regular intervals (4 to 6 weeks) are required to achieve desired results.
Triamcinolone is a steroid injection.
Intravitreal triamcinolone is an injection of the steroid drug into the vitreous cavity of your eye. It can be used to reduce macular oedema (swelling) that may occur in diabetes or retinal vein occlusion or other macular disease.
OZURDEX® is a biodegradable implant injected into the eye (vitreous) to treat adults with macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) and to treat adults with non-infectious uveitis affecting the posterior segment of the eye.
Features of Orzudex:
- Potent anti-inflammatory corticosteroid dexamethasone
- Biodegradable intravitreal implant
- Small implant that is less than 0.5mm wide and ~6.0mm long
- Does not require surgical removal
In clinical trials, OZURDEX® intravitreal implants improved the vision of many patients. It’s important to remember that each case of retinal vein occlusion or noninfectious posterior segment uveitis is unique. Your own results may vary.